The European Commission has applied to increase the fees payable to EMA by 0.2%, which in line with the 2015 inflation rate.
You’ve only got another two weeks to submit applications to the European Medicines Agency (EMA) before the fees go up. The new charges for all applications except pharmacovigilance procedures will take effect on April 1.
The European Commission has applied to increase the fees payable to EMA by 0.2%, which in line with the 2015 inflation rate. EMA has said it will publish full details of the revised fees at the end of March, once the European Commission has adopted the regulation and published it in the Official Journal of the European Union and the Agency's Management Board has reached a decision on its implementation.
All applications received by March 31 will be charged at the current fee and reduction rates, according to EMA. For scientific advice and protocol assistance, the cut-off date will be the date of validation of the request for advice. For annual fees, the anniversary date defines the applicable fee and consequently any anniversary on or after April 1, 2016 will attract the new fee.
Fees charged for pharmacovigilance procedures in accordance with Regulation (EU) 658/2014 are expected to be updated from July 1, 2016.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.